Which antibiotic combo is safer for your kidneys? new trial aims to find out

NCT ID NCT07556107

Not yet recruiting Disease control Sponsor: Bassett Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. The goal is to help doctors make safer treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vancomycin combined with either piperacillin/tazobactam or meropenem
What this could lead to: If it works, this could help doctors choose the safer antibiotic combination to reduce kidney damage in hospitalized patients.
What could go wrong: This is a Phase 4 trial comparing already-approved drugs, so no major breakthrough is expected. Results may show no clear difference or may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury Infections infectious disease infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY INFECTION SEPSIS

Contacts and locations

Locations

Bassett Medical Center

Cooperstown, New York, 13326, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.